Understanding and treating jaw bone damage related to certain medications
Osteomucosal healing and immunity in medication-related osteonecrosis of the jaw
['FUNDING_OTHER'] · UNIVERSITY OF CALIFORNIA LOS ANGELES · NIH-10870267
This study is looking into how certain medications can lead to a serious jaw condition called MRONJ, and it's for people who have been using these medications for a long time; the researchers want to understand the immune system's role in this issue and find new treatments to help prevent or lessen the problem.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA LOS ANGELES (nih funded) |
| Locations | 1 site (LOS ANGELES, UNITED STATES) |
| Trial ID | NIH-10870267 on ClinicalTrials.gov |
What this research studies
This research investigates medication-related osteonecrosis of the jaw (MRONJ), a serious condition that can occur after long-term use of medications like bisphosphonates. The study aims to uncover the underlying immune mechanisms that contribute to MRONJ and explore targeted immunotherapies that could prevent or mitigate this condition. By using advanced mouse models, the researchers will analyze how specific immune responses are altered in patients with MRONJ. The ultimate goal is to develop effective treatments that improve patient outcomes and quality of life.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have been prescribed bisphosphonates or denosumab for osteoporosis or bone malignancies.
Not a fit: Patients who have not used anti-resorptive medications or those without a diagnosis related to jaw bone health may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that prevent or reduce the severity of jaw bone damage in patients taking certain medications.
How similar studies have performed: Previous research has indicated that understanding immune mechanisms can lead to breakthroughs in treating similar conditions, suggesting a promising avenue for this investigation.
Where this research is happening
LOS ANGELES, UNITED STATES
- UNIVERSITY OF CALIFORNIA LOS ANGELES — LOS ANGELES, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KIM, REUBEN HAN-KYU — UNIVERSITY OF CALIFORNIA LOS ANGELES
- Study coordinator: KIM, REUBEN HAN-KYU
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer